184 participants
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-09-01
- Start Date:
- 2024-11-08
- Completion:
- 2028-07-15
Conditions
- Progressive Glioblastoma
- Recurrent Glioblastoma
Interventions
- PROCEDURE
- DRUG
- BIOLOGICAL
No Results Yet